INTRODUCTION: Prostate cancer (PCa) is the most common disease in male patients and it has the particularity to be androgen dependent.
The aim of the current study was to provide an overview about the interest of testosterone dosage during the management of PCa regardless of the stage of the disease.
PATIENTS AND METHODS: A systematic review of the literature was done from the PubMed database by searching the following key words alone or in combination: prostate cancer; testosterone; risk; aggressiveness; hormonotherapy; active surveillance; prognosis; androgen; cardiovascular risk; biochemical recurrence.
RESULTS: The level of plasmatic testosterone depends on the moment of the day with a peak between the end of the night and in the morning. We can test either the whole testosterone level, the free testosterone level or the bioavailable testosterone. The bioavailable testosterone is more representative of the presence of androgen in tissues but a specialized laboratory is mandatory. The testosterone plasmatic rate is potentially useful during several steps of the PCa management: in localized prostate cancer cases, men with low testosterone levels are more likely to have an aggressive disease and are therefore not good candidates for active surveillance. An extensive radical prostatectomy should be considered in case of young men since these patients are more likely to recur subsequently; in advanced prostate cancer cases, a testosterone level has to be less or equal to 0.2ng/mL to guarantee an appropriate castration when a patient is undergoing an androgen deprivation treatment. A dissociation between the trend of PSA and testosterone levels can be the starting point of the castration-resistant period of the disease.
CONCLUSION: The testosterone level can bring useful information regarding the profile of PCa and its ability to evolve during the whole natural history of the disease.
Written by:
Lasselin J, Drouin SJ, Champy CM, Léon P, Casenave J, Cussenot O, Bitker MO, Rouprêt M. Are you the author?
Service d'urologie, l'hôpital Pitié-Salpêtrière, Assistance publique-Hôpitaux de Paris, groupe de recherche GRC 5 oncotype, institut universitaire de cancérologie de l'UPMC, faculté de médecine Pierre-et-Marie-Curie, université Paris VI, bâtiment Gaston-Cordier, 83, boulevard de l'Hôpital, 75013 Paris, France.
Reference: Prog Urol. 2013 Jun;23(7):438-43.
doi: 10.1016/j.purol.2013.01.007
PubMed Abstract
PMID: 23721702
UroToday.com Prostate Cancer Section
